The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health•

Category: Clinical & Manufacturing

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
Clinical & Manufacturing

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

OCT 16, 2026
New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia
Clinical & Manufacturing

New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia

SEP 24, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Clinical & Manufacturing

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions
Clinical & Manufacturing

GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions

SEP 11, 2026
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics
Clinical & Manufacturing

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics

SEP 4, 2026
Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data
Clinical & Manufacturing

Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data

AUG 7, 2026
Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial
Clinical & Manufacturing

Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial

JUN 8, 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS
Clinical & Manufacturing

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS

APR 30, 2026
Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure
Clinical & Manufacturing

Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure

APR 16, 2026
Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
Biotics and Supplements

Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence

MAR 24, 2026
EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS
Clinical & Manufacturing

EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS

JAN 8, 2026